Publications

Found 92 results
Type [ Year(Asc)]
2010
Gersbach, CA, Gaj, T, Gordley, RM, and Barbas, CF. "Directed evolution of recombinase specificity by split gene reassembly." Nucleic Acids Research 38, no. 12 (2010): 4198-4206.
2009
Gordley, RM, Gersbach, CA, and Barbas, CF. "Synthesis of programmable integrases." Proceedings of the National Academy of Sciences of USA 106, no. 13 (2009): 5053-5058.
2007
Gersbach, CA,, Le Doux, JM, and García, AJ. "Biomaterial-mediated retroviral gene transfer using self-assembled monolayers." Biomaterials 28, no. 34 (2007): 5121-5127.
Gersbach, CA, Phillips, JE, and García, AJ. "Genetic engineering for skeletal regenerative medicine." Annual Review of Biomedical Engineering 9 (2007): 87-119.
Pregizer, S, Barski, A, Gersbach, CA, García, AJ, and Frenkel, B. "Identification of novel Runx2 targets in osteoblasts: cell type-specific BMP-dependent regulation of Tram2." Journal of Cellular Biochemistry 102, no. 6 (2007): 1458-1471.
Gersbach, CA, Guldberg, RE, and García, AJ. "In vitro and in vivo osteoblastic differentiation of BMP-2- and Runx2-engineered skeletal myoblasts." Journal of Cellular Biochemistry 100, no. 5 (2007): 1324-1336.
Phillips, JE, Gersbach, CA, and García, AJ. "Virus-based gene therapy strategies for bone regeneration." Biomaterials 28, no. 2 (2007): 211-229.
2006
Phillips, JE, Gersbach, CA, Wojtowicz, AM, and García, AJ. "Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation." Journal of cell science 119, no. Pt 3 (2006): 581-591.
Gersbach, CA, Le Doux, JM, Guldberg, RE, and García, AJ. "Inducible regulation of Runx2-stimulated osteogenesis." Gene Therapy 13, no. 11 (2006): 873-882.
2005
Lan, MA, Gersbach, CA, Michael, KE, Keselowsky, BG, and García, AJ. "Myoblast proliferation and differentiation on fibronectin-coated self assembled monolayers presenting different surface chemistries." Biomaterials 26, no. 22 (2005): 4523-4531.
Gersbach, CA, Phillips, JE, Guldberg, RE, and García, AJ. "Runx2-genetically engineered cells for bone tissue engineering." Proceedings of the 2005 Summer Bioengineering Conference 2005 (2005): 603-604.
Drevs, J, Zirrgiebel, U, Schmidt-Gersbach, CIM, Mross, K, Medinger, M, Lee, L, Pinheiro, J, Wood, J, Thomas, AL, Unger, C et al. "Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials." Annals of Oncology 16, no. 4 (2005): 558-565.
2004
Gersbach, CA. "Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Exp. Cell Res. 300 (2004): 406-417.
Gersbach, CA, Byers, BA, Pavlath, GK, and García, AJ. "Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Experimental Cell Research 300, no. 2 (2004): 406-417.
Gersbach, CA, Byers, BA, Pavlath, GK, Guldberg, RE, and García, AJ. "Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro." Biotechnology & Bioengineering 88, no. 3 (2004): 369-378.
Gersbach, CA, Byers, BA, Guldberg, RE, Pavlath, GK, and García, AJ. "Runx2-stimulated transdifferentiation of primary skeletal myoblasts into an osteoblastic mineralizing phenotype for bone tissue engineering." Transactions - 7th World Biomaterials Congress (2004).
2003
García, AJ, Guldberg, RE, Byers, BA, Gersbach, CA, and Phillips, JE. "Addressing cell-sourcing limitations with gene therapy." IEEE Engineering in Medicine and Biology Magazine 22, no. 5 (2003): 65-70.

Pages